What is the market's earnings forecast for Champions Oncology next quarter?

What factors drove the changes in Champions Oncology's revenue and profit?

What does Champions Oncology do and what are its main business segments?

What is Champions Oncology's latest dividend and current dividend yield?

What were the key takeaways from Champions Oncology’s earnings call?

What is Champions Oncology's gross profit margin?

Did Champions Oncology beat or miss consensus estimates last quarter?

What guidance did Champions Oncology's management provide for the next earnings period?

- **Revenue Resilience**: Core services revenue up 32% YoY, offsetting data revenue decline, with Q3 EBITDA positive for the third straight quarter.
- **Data Business Breakthrough**: First 6-figure data deal for Q4 and incremental revenue from prior large deal, signaling commercial viability.
- **Cost Efficiency**: Outsourced lab costs ($2 million)拖累 gross margin至47%, but in-house transition could improve margins to >50%.
- **Corellia Funding**: Active discussions for external financing, with potential redeployment of EBITDA into data initiatives or bottom-line growth.

**【CEO Summary Section】**
- **Record Services Revenue**: Q3 services revenue reached a record $16.6 million, driven by strong study execution and backlog conversion, despite a 3% YoY decline in total revenue due to a large data deal from Q3 2025.
- **Operational Efficiency**: Achieved third consecutive quarter of positive adjusted EBITDA ($575,000) with no headcount additions, showcasing operating leverage.
- **Data Business Momentum**: Closed a 6-figure data deal for Q4 recognition and expects incremental revenue from a prior large deal, signaling early traction.
- **Corellia Progress**: Target discovery subsidiary receives positive feedback, with potential external funding discussions ongoing, though timing uncertain.

**【CFO Financial Commentary】**
- **Revenue Mix**: Core study revenue grew 32% YoY to $16.6 million, offsetting zero data revenue this quarter (vs. $4.5 million last year).
- **Gross Margin**: 47% due to $2 million in outsourced lab costs; internalizing this work could boost margin to >50%.
- **Operating Expenses**: Increased 36% YoY to $7.2 million, driven by R&D ($1.2 million), sales/marketing, and G&A investments.
- **Cash Position**: $7.1 million in cash, with net cash used in operations of $1.4 million.

**【Q&A Highlights】**
- No questions were asked during the call, with closing remarks emphasizing Q4 execution and long-term growth drivers.

Champions Oncology, Inc.(CSBR)-20260313-2026 Q3 Earnings call transcript

- **Revenue Growth**: Q2 revenue up 11% YoY to $15M, driven by reduced cancellations
- **Profitability**: 52% gross margin (vs. 45% last year), $800K adjusted EBITDA
- **Strategic Investments**: 
  - $900K in data platform sequencing
  - New GM from Illumina to lead data monetization
  - Radiolabeling segment scaling with in-house capabilities
- **Market Momentum**: Pharma R&D outsourcing expected to increase (1/3 of biotechs surveyed)
- **Margin Outlook**: Core services margin stable at 50-52%, data business could drive margin expansion

**【CEO Opening Remarks】**
- **Core Strategic Goals**: 
  1. Deliver year-over-year revenue growth (Q2: +11% YoY to $15M) with margin leverage in core TOS business.
  2. Invest in growth levers like data platforms to expand biopharma partnerships.
  3. Maintain full-year positive adjusted EBITDA (~$800K Q2) without shareholder dilution.
- **Market Trends**: Pharma/biotech R&D budgets gradually improving; 2026 calendar-year booking momentum cautiously optimistic.
- **Key Q2 Highlights**: 
  - 52% gross margin (vs. 45% last year) driven by operational efficiency
  - Radiolabeling segment growing as one of few approved labs, with in-house work reducing outsourcing costs
  - Data platform investments (new GM hire from Illumina) targeting translational insights for pharma

**【CFO Financial Commentary】**
- **Revenue & Profitability**: 
  - Q2 revenue $15M (+11% YoY), driven by reduced cancellations
  - Adjusted EBITDA $800K (on track for full-year positive)
  - Gross margin 52% (flat COGS vs. +11% revenue)
- **Cost Structure**: 
  - OpEx $7M (+$2M YoY): 
    - R&D +$900K (data platform sequencing)
    - G&A +$800K (leadership transitions, IT)
    - Sales +$100K (commercial team expansion)
- **Cash Flow**: $8.5M cash on hand, no debt

**【Q&A Highlights】**
1. **Market Opportunity Conversion**: 
   - RFP volume improving, but cautious on timing to double-digit growth
   - 1/3 of biotech execs surveyed plan to increase outsourcing
2. **Data Platform Strategy**: 
   - New GM (Tammer Farid) focused on monetizing PDX + data platform
   - Investments in commercial team to accelerate data sales
3. **Margin Outlook**: 
   - Core services gross margin ~50-52% (stable)
   - Data business could lift overall margins
   - One-time costs from radiolabeling transition may impact Q3 margins

Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript

- **Revenue Rebound**: $14M Q1 2026, up from $12.4M Q4 2025, driven by TOS and data platform.
- **Gross Margin Expansion**: 43% (vs. 50% prior year), with improvement expected as radiopharma work shifts in-house.
- **Data Platform Growth**: 3 consecutive quarters of sales; AI/ML-driven drug discovery opportunities.
- **Corellia Potential**: Compelling in vivo data; exploring external funding to accelerate pipeline.
- **Cash Strength**: $10.3M debt-free; expect H2 cash growth with margin expansion.

**【CEO Opening Remarks】**
- Q1 2026 revenue of $14 million, rebounding from Q4 2025 softness, driven by TOS (tumor organoid system) business and emerging data platform.
- Radiopharma services expansion: 30+ PDX models enable end-to-end workflows, reducing costs and improving gross margins by bringing work in-house.
- Data platform momentum: 3 consecutive quarters of sales since first licensing deal; AI/ML-driven drug discovery opportunities with unique PDX bank data.
- Corellia drug discovery subsidiary advancing; compelling in vivo data despite biotech funding challenges.

**【CFO Financial Commentary】**
- Q1 GAAP revenue $14M (flat vs. Q1 2025), with $13.7M from research services and $0.3M from data.
- Adjusted EBITDA $60K (vs. $2M prior year), driven by $600K non-cash expenses (stock comp, depreciation).
- Gross margin 43% (vs. 50% prior year) due to higher outsourced lab costs for radio labeling.
- Operating expenses up 17% to $6M: R&D +$600K (data platform), S&M +$200K (business dev), G&A +$200K (IT inefficiencies).
- Cash $10.3M (unchanged from Q4), debt-free; expect cash neutral Q2, growth in H2 with margin expansion.

**【Q&A Highlights】**
- **Data Business Strategy**: No changes to go-to-market; early wins and pipeline building, but size of opportunity TBD.
- **Corellia Funding**: Exploring external partnerships/royalty models to accelerate drug discovery.
- **Market Environment**: Cautiously optimistic on biotech R&D recovery; customer cancellations down, bookings conversion improving.
- **2026 Outlook**: Sequential revenue growth, margin expansion as radio labeling shifts in-house; data deals key to top-line growth.

Champions Oncology, Inc. (CSBR) Q1 2026 Earnings Call Transcript

- **Turnaround Achieved**: 14% revenue growth to $57 million, first profitable year since 2024, with 50% gross margin.
- **New Growth Engines**: Radiopharma services (50-60% margin) and data licensing ($4.7 million+ in FY2026) driving diversification.
- **CEO Transition**: Ronnie Morris stepping down, Rob Brainin to lead data monetization and strategic growth.
- **Market Resilience**: Reduced cancellations, improved bookings conversion, and big pharma focus mitigating macro risks.
- **Financial Strength**: $9.8 million cash, no debt, and expectations for sequential revenue and margin growth in FY2026.

**【CEO Summary Section】**
- Fiscal 2025 marked a turnaround with 14% revenue growth to $57 million and return to profitability, driven by core services and new data licensing deals.
- Launched radiopharmaceutical services platform, leveraging PDX models for radiopharma testing, with high-margin potential (50-60%).
- CEO transition: Ronnie Morris stepping down, Rob Brainin to lead, focusing on data monetization and service expansion.
- Strategic focus on big pharma partnerships, reduced customer cancellations, and improved bookings-to-revenue conversion.

**【CFO Financial Commentary】**
- FY2025: Adjusted EBITDA of $7.1 million (vs. -$3.9M in FY2024), 50% gross margin (up from 42%), and $9.8 million cash (vs. $2.6M prior year).
- Q4 2025: Revenue $12.1 million (down 14% YoY), 41% gross margin (vs. 48% prior year), and $1.2 million adjusted EBITDA loss.
- Cost control: $3.4 million operating expense reduction, offset by $500,000 sales/marketing investment for data licensing pipeline.
- FY2026 outlook: Sequential revenue growth, margin expansion, and cash neutrality in Q1 with expected growth in H2.

**【Q&A Key Highlights】**
- **Market Environment**: Cautious optimism amid biotech R&D budget constraints, but improving opportunity generation and big pharma engagement.
- **Data Licensing Pipeline**: Expect $4.7 million+ in FY2026, with smaller deals closing faster and larger deals in pipeline.
- **Radiopharma Services**: High-margin (50-60%) with capacity-constrained demand, leveraging PDX models for radiopharma testing.
- **Capital Allocation**: Focus on data creation and high-margin service expansion, with no significant capex planned.
- **Corellia AI Update**: Actively raising capital for drug development programs, leveraging PDX insights to identify high-potential compounds.

Champions Oncology (CSBR) Q4 2025 Earnings Call Transcript

- **Record Q3 Performance**: $17M revenue, $4.5M data licensing deal, and 61% gross margin highlight strategic pivot to data monetization.
- **Operational Excellence**: 13% margin expansion in core services, $3.8M YoY opex reduction, and $5.2M EBITDA reflect disciplined execution.
- **AI-Driven Data Growth**: Deep multiomic dataset now powers external AI applications, with pipeline of multi-million dollar licensing opportunities.
- **Capital Structure Optimization**: Subsidiary spin-out preserves core business strength while unlocking drug development value.
- **Sector Outlook**: Biopharma R&D recovery underway, but biotech funding challenges persist.


**【CEO Summary Section】**
- Q3 2025 marked a transformative quarter with record revenue of $17 million, driven by the successful closure of the first data licensing deal and core services growth.
- Core services revenue grew 4% YoY to $12.5 million, with a 13% improvement in research service margins to 48%, reflecting operational efficiency gains.
- The company's PDX bank and deep multiomic data set are key differentiators, with AI-driven demand for data increasing. The first data licensing deal of $4.5 million highlights the potential of this new revenue stream.
- A cautiously optimistic outlook for the biopharma sector, with early signs of R&D budget expansion, though challenges remain in the biotech funding environment.

**【CFO Financial Commentary】**
- GAAP income from operations improved to $4.5 million (vs. -$2.6 million YoY), with adjusted EBITDA reaching $5.2 million, a 343% YoY increase.
- Gross margin expanded to 61%, driven by high-margin data revenue, with research service margins improving to 48% (vs. 35% YoY).
- Operating expenses were tightly controlled, with R&D down 21% to $1.7 million and G&A reduced 11% to $1.8 million, reflecting disciplined cost management.
- Cash position strengthened to $3.2 million, with $900,000 generated from operations, despite a $500,000 investment in growth initiatives.

**【Q&A Key Highlights】**
- **Data Licensing Deal Structure**: First deal was a one-time fee for access to a portion of the multiomic data set. Pipeline includes discussions with multiple pharma/biotech customers for both one-time and royalty-based arrangements.
- **Market Position**: Champions' deep, multi-layered tumor data (e.g., genomics, proteomics, response data) provides unique value compared to competitors' broad but shallow datasets.
- **AI Impact**: While AI is enhancing data utility, it has not yet significantly impacted core services workflows.
- **Corellia Subsidiary**: Raising capital for drug development subsidiary via external funding, with Champions retaining an ownership stake. Deal expected to enhance long-term value without impacting parent company cash flow.
- **Industry Trends**: Biopharma R&D spending shows early signs of recovery, but biotech sector remains constrained by funding challenges.


Actual								0.05	-0.17	0.02	0.01	0.07	-0.03	0.01	0.03	0.07	-0.02	0	0.01	-0.16	-0.17	-0.16	-0.15	-0.16	0.01	0.11	0.05	0.36	-0.07	0.02	0.06	-0.02
Forecast								0.0367	0.02	-0.0067	0.0033	0.0067	-0.0133	0.01	0.02	0.0533	0.035	0.0033	0.0067	-0.03	-0.08	-0.105	-0.1633	-0.06	-0.16	-0.03	0.01	-0.01	-0.2	-0.01	0	0.09
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+36.24%	-950.00%	+398.51%	+203.03%	+944.78%	-125.56%	0.00%	+50.00%	+31.33%	-157.14%	-100.00%	+49.25%	-433.33%	-112.50%	-52.38%	+8.14%	-166.67%	+106.25%	+466.67%	+400.00%	+3700.00%	+65.00%	+300.00%	0.00%	-122.22%

CSBR

CSBR fundamentals

CSBR Q3 2026 Earnings

Earnings Call

You can ask Aime

CSBR

CSBR fundamentals

CSBR Q3 2026 Earnings

Earnings Call

CSBR Earnings Call Summary for Q3/20264:30 PM on Mar 12, 2026

CSBR Earnings Call Summary for Q2/20264:30 PM on Dec 15, 2025

CSBR Earnings Call Summary for Q1/20264:30 PM on Sep 15, 2025

CSBR Earnings Call Summary for Q4/20254:30 PM on Jul 23, 2025

CSBR Earnings Call Summary for Q3/20254:30 PM on Mar 11, 2025

You can ask Aime